Skip to main content
ISTH 2023 Main banner
Back

    State-of-the-Art Session

    Hemophilia and Rare Bleeding Disorders

    Inhibitors and How Do We Deal With Them in 2023

    SOA 25.3 - Hemophilia B: Where Are We at With Inhibitor Development and Eradication?

    Wednesday, June 28, 2023
    09:20 – 09:45 ET
    Room: 516
    Session Available As: Live-Stream and On-Demand
    Please view the 2023 RPTH State-of-the-Art Illustrated Capsules here.

    Learning Objectives:

    • Upon completion of the session, the participant will be able to understand the pathophysiology and clinical presentation of inhibitor development in patients with haemophilia B in comparison to haemophilia A
    • Upon completion of the session, the participant will achieve knowledge on different treatment strategies for patients with haemophilia B and inhibitors, especially on different immune tolerance induction (ITI) protocols with or without immunosuppression as well as upcoming alternative strategies for bleeding prophylaxis.
    • Upon completion of the session, the participant will be able to council a patient or his family on treatment options, particularly to explain potential benefits, risks, and side effects associated with an attempt of inhibitor eradication.